Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …

Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …

USP8 is a deubiquitinating enzyme in the family of ubiquitin-specific proteases (USPs)
which can remove ubiquitin from the substrate and protect the substrate from degradation …

The proliferation of targeted anticancer agents over the last two decades has revolutionized
cancer treatment and improved survival in many previously refractory malignancies …

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small
cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which …

Introduction: EGFR is the receptor for epidermal growth factor (EGF) and belongs to the
protein tyrosine kinase (PTK) receptor. It is closely related to the inhibition of tumor cell …

Aims Both gefitinib and afatinib are epidermal growth factor tyrosine kinase inhibitors (EGFR-
TKI) in the treatment of non-small cell lung cancer (NSCLC). It has been reported that …

Introduction Recently, a phase III CROWN trial compared the efficacy of two anaplastic
lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical …